Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial have?
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial has 886 citations in the OpenAlex counts ScholarIQ stores.
When was Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial published?
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial has 2007 year in the ScholarIQ index.
What is the open-access status of Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial?
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial has closed oa status in the ScholarIQ index.
What is the DOI of Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial?
The DOI for Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial is on the source record.
What is the PMID of Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial?
The PMID for Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial is on the source record.
What is the OpenAlex record for Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial?
The OpenAlex for Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial is on the source record.